Purevax RCP


vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.

This document cannot replace a face-to-face discussion with your veterinarian. If you need more information about your animal’s medical condition or treatment, contact your veterinarian. If you want more information on the basis of the CVMP recommendations, read the scientific discussion (also part of the EPAR).

This EPAR was last updated on 30/04/2018

Authorisation details

Product details
Purevax RCP
Agency product number
Active substance
  • attenuated feline rhinotracheitis herpesvirus (FHV F2 strain) / inactivated feline calicivirosis antigens (FCV 431 and G1 strains)
  • attenuated feline panleucopenia virus (PLI IV)
International non-proprietary name (INN) or common name
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia
Anatomical therapeutic chemical veterinary (ATCvet) codes
Publication details
Marketing-authorisation holder
Date of issue of marketing authorisation valid throughout the European Union
Contact address

29 Avenue Tony Garnier
69007 Lyon

Product information

15/01/2015 Purevax RCP - EMEA/V/C/000090 - WS-0606


Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Active immunisation of cats aged eight weeks and older:

  • against feline viral rhinotracheitis to reduce clinical signs;
  • against calicivirus infection to reduce clinical signs and excretion;
  • against feline panleucopenia to prevent mortality and clinical signs.

Onsets of immunity have been demonstrated one week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.

The duration of immunity is three years after the last re-vaccination.

Assessment history

How useful was this page?

Add your rating